Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Article number	3003
Journal	Journal of Clinical Oncology
Volume	38
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2020.38.15_suppl.3003
Publication status	Published - 2020

Access to Document

@article{b9cf00e18c9e4c6bb8aaaab2b8c2eac8,

title = "Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.",

author = "J Voortman",

year = "2020",

doi = "10.1200/JCO.2020.38.15_suppl.3003",

language = "English",

volume = "38",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

TY - JOUR

T1 - Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

AU - Voortman, J

PY - 2020

Y1 - 2020

U2 - 10.1200/JCO.2020.38.15_suppl.3003

DO - 10.1200/JCO.2020.38.15_suppl.3003

M3 - Meeting Abstract

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

M1 - 3003

ER -